TY - JOUR
T1 - Skeletogenic Capacity of Human Perivascular Stem Cells Obtained Via Magnetic-Activated Cell Sorting
AU - Meyers, Carolyn A.
AU - Xu, Jiajia
AU - Zhang, Leititia
AU - Chang, Leslie
AU - Wang, Yiyun
AU - Asatrian, Greg
AU - Ding, Catherine
AU - Yan, Noah
AU - Zou, Erin
AU - Broderick, Kristen
AU - Lee, Min
AU - Peault, Bruno
AU - James, Aaron W.
N1 - Publisher Copyright:
Copyright © 2019 Mary Ann Liebert, Inc.
PY - 2019/12
Y1 - 2019/12
N2 - Human perivascular stem/stromal cells (PSC) are a multipotent mesenchymal progenitor cell population defined by their perivascular residence. PSC are increasingly studied for their application in skeletal regenerative medicine. PSC from subcutaneous white adipose tissue are most commonly isolated via fluorescence-activated cell sorting (FACS), and defined as a bipartite population of CD146+CD34-CD31-CD45- pericytes and CD34+CD146-CD31-CD45- adventitial cells. FACS poses several challenges for clinical translation, including requirements for facilities, equipment, and personnel. The purpose of this study is to identify if magnetic-activated cell sorting (MACS) is a feasible method to derive PSC, and to determine if MACS-derived PSC are comparable to our previous experience with FACS-derived PSC. In brief, CD146+ pericytes and CD34+ adventitial cells were enriched from human lipoaspirate using a multistep column approach. Next, cell identity and purity were analyzed by flow cytometry. In vitro multilineage differentiation studies were performed with MACS-defined PSC subsets. Finally, in vivo application was performed in nonhealing calvarial bone defects in Scid mice. Results showed that human CD146+ pericytes and CD34+ adventitial cells may be enriched by MACS, with defined purity, anticipated cell surface marker expression, and capacity for multilineage differentiation. In vivo, MACS-derived PSC induce ossification of bone defects. These data document the feasibility of a MACS approach for the enrichment and application of PSC in the field of tissue engineering and regenerative medicine.
AB - Human perivascular stem/stromal cells (PSC) are a multipotent mesenchymal progenitor cell population defined by their perivascular residence. PSC are increasingly studied for their application in skeletal regenerative medicine. PSC from subcutaneous white adipose tissue are most commonly isolated via fluorescence-activated cell sorting (FACS), and defined as a bipartite population of CD146+CD34-CD31-CD45- pericytes and CD34+CD146-CD31-CD45- adventitial cells. FACS poses several challenges for clinical translation, including requirements for facilities, equipment, and personnel. The purpose of this study is to identify if magnetic-activated cell sorting (MACS) is a feasible method to derive PSC, and to determine if MACS-derived PSC are comparable to our previous experience with FACS-derived PSC. In brief, CD146+ pericytes and CD34+ adventitial cells were enriched from human lipoaspirate using a multistep column approach. Next, cell identity and purity were analyzed by flow cytometry. In vitro multilineage differentiation studies were performed with MACS-defined PSC subsets. Finally, in vivo application was performed in nonhealing calvarial bone defects in Scid mice. Results showed that human CD146+ pericytes and CD34+ adventitial cells may be enriched by MACS, with defined purity, anticipated cell surface marker expression, and capacity for multilineage differentiation. In vivo, MACS-derived PSC induce ossification of bone defects. These data document the feasibility of a MACS approach for the enrichment and application of PSC in the field of tissue engineering and regenerative medicine.
KW - MACS
KW - bone regeneration
KW - bone tissue engineering
KW - magnetic activated cell sorting
KW - mesenchymal stem cell
KW - mesenchymal stromal cell
UR - http://www.scopus.com/inward/record.url?scp=85074480458&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85074480458&partnerID=8YFLogxK
U2 - 10.1089/ten.tea.2019.0031
DO - 10.1089/ten.tea.2019.0031
M3 - Article
C2 - 31020920
AN - SCOPUS:85074480458
SN - 1937-3341
VL - 25
SP - 1658
EP - 1666
JO - Tissue Engineering - Part A
JF - Tissue Engineering - Part A
IS - 23-24
ER -